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Abstract
Background: The glutamatergic dysfunction hypothesis of schizophrenia suggests that genes
involved in glutametergic transmission are candidates for schizophrenic susceptibility genes. We
have been performing systematic association studies of schizophrenia with the glutamate receptor
and transporter genes. In this study we report an association study of the excitatory amino acid
transporter 2 gene, SLC1A2 with schizophrenia.
Methods: We genotyped 100 Japanese schizophrenics and 100 controls recruited from the
Kyushu area for 11 single nucleotide polymorphism (SNP) markers distributed in the SLC1A2 region
using the direct sequencing and pyrosequencing methods, and examined allele, genotype and
haplotype association with schizophrenia.The positive finding observed in the Kyushu samples was
re-examined using 100 Japanese schizophrenics and 100 controls recruited from the Aichi area.
Results: We found significant differences in genotype and allele frequencies of SNP2 between
cases and controls (P = 0.013 and 0.008, respectively). After Bonferroni corrections, the two
significant differences disappeared. We tested haplotype associations for all possible combinations
of SNP pairs. SNP2 showed significant haplotype associations with the disease (P = 9.4 × 10-5, P =
0.0052 with Bonferroni correction, at the lowest) in 8 combinations. Moreover, the significant
haplotype association of SNP2-SNP7 was replicated in the cumulative analysis of our two sample
sets.
Conclusion: We concluded that at least one susceptibility locus for schizophrenia is probably
located within or nearby SLC1A2 in the Japanese population.
Background
Schizophrenia is a severe mental disorder characterized by
hallucinations, delusions, disorganized thoughts, and var-
ious cognitive impairments. The life-time prevalence is
about 1%, and genetic factors were known to play a criti-
cal role in its pathogenesis [1]. Based on the fact that
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sis, a glutamatergic dysfunction hypothesis has been pro-
posed for the pathogenesis of schizophrenia [2-4]. This
hypothesis has been supported by recent multiple reports
of association of schizophrenia with glutamate receptor
genes and with the genes related to glutamatergic trans-
mission, such as G72 and NRG1 [5-10].
In addition, other synaptic elements related to glutamate,
such as excitatory amino acid transporters (EAATs), also
potentially affect glutamatergic neurotransmission. EAATs
maintain extracellular glutamate concentrations within
physiological levels by reuptaking the synaptically
released glutamate. A deficient uptake has been impli-
cated in the pathogenesis of ischemic brain damage [11]
and may be involved in neurodegenerative diseases such
as amyotrophic lateral sclerosis (ALS) [12]. Recently sig-
nificant increases of mRNA expression of EAAT1 and
EAAT2 have been reported in the thalamus of schizo-
phrenics, suggesting the possibility that an excessive gluta-
mate uptake is involved in schizophrenia [13]. On the
other hand, a significant decrease of EAAT2 mRNA expres-
sion was observed in the parahippocampal gyrus of schiz-
ophrenics [14]. Therefore the EAAT genes are reasonable
candidates for schizophrenia, as well as glutamate recep-
tor genes.
The EAATs family consists of five members (EAAT1-
EAAT5). Their cellular localizations are different: EAAT1
and EAAT2 are astroglial, whereas EAAT3 EAAT4 and
EAAT5 are neuronal [25]. Since EAAT2 accounts for
approximately 90% of glutamate reuptake in the rodent
forebrain [16,17], we focused on the EAAT2 gene
(SLC1A2) in association studies of schizophrenia. SLC1A2
has been mapped to 11p13-p12 [18] and consists of 11
exons spanning over 165 kb. In this study we tested asso-
ciations of schizophrenia with 11 SNPs distributed in
SLC1A2 with an average interval of 15.9 kb. To enhance
the detection power of the study, we also examined the
haplotype associations of the SNPs with the disease.
Methods
Human subjects
Blood samples were obtained from unrelated Japanese
individuals who had provided written informed consent.
We used two Japanese sample sets in this study. In the first
one, Kyushu samples, 100 schizophrenia patients (mean
age 49.5; 44.0% female) were recruited from hospital in
the Fukuoka and Oita areas and 100 healthy unrelated
controls (mean age 51.2; 44.0% female) were recruited
from the Fukuoka area. In the initial SNP selection proc-
ess, we used another 16 Japanese samples which are
recruited in the Fukuoka area and informed in the same
way. In the second one, Aichi samples, 100 schizophrenia
patients (mean age 34.4; 44% female) and 100 healthy
unrelated controls (mean age 39.9; 45% female) were col-
lected in the Aichi area about 600 km east of Fukuoka. All
patients fulfilled the DSM-IV criteria for schizophrenia
[19]. All of the case and control samples are ethnically Jap-
anese. DNA samples were purified from whole peripheral
blood by the method previously described [20]. This
study was approved by the Ethics Committee of Kyushu
University, Faculty of Medicine and the Fujita Health Uni-
versity Ethics Committee.
SNP selection in the SLC1A2 region
We retrieved the primary SNP information from the
dbSNP database http://www.ncbi.nlm.nih.gov/SNP/.
Assuming the same size of the half length of linkage dise-
quilibrium (LD) (60 kb) as reported in Caucasians [21],
we initially intended to select common SNPs every 50 kb
in SLC1A2. We tested 22 candidate SNPs including all of
the exonic SNPs, in the 16 healthy Japanese samples by
the direct sequencing method. Out of the 22 SNPs we
selected the following 7 common SNPs with minor allele
frequencies over 10% for further analyses: SNP1,
rs1923295; SNP3, rs4534557; SNP6, rs1885343; SNP8,
rs752949; SNP9, rs1042113; SNP10, rs3838796; SNP11,
rs1570216. We also identified a novel SNP, SNP7, in
intron 1 (conting location: 34105026). After the LD anal-
yses described below, we noticed LD gaps (D' < 0.3) of the
initial SNP set and examined additional 20 candidate
SNPs. Out of the 20 SNPs, we selected the following 3
SNPs to fill the LD gaps: SNP2, rs4755404; SNP4,
rs4756224; SNP5, rs1923298. The locations of the total
11 SNPs are shown in Figure 1.
Genotyping
Eleven SNPs were amplified as 11 individual fragments by
PCR using the primers shown in Table 1 - additional file
1. The reaction mixture for PCR was prepared in a total
volume 10 µl with 5 ng of genomic DNA, 10 pmol of each
primer (4 pmol of SNP3), 2.5 mM of MgCl2, 0.2 mM of
each dNTP and 0.25 U of Taq DNA polymerase. An initial
denaturing step of 1 min at 94°C was followed by 30, 35
or 40 cycles of 94°C for 30 sec, appropriate annealing
temperature for 30 sec and 72°C for 30 sec. A final exten-
sion step was carried out at 72°C for 7 min. The nucle-
otide sequences of each primer, PCR conditions and
genotyping methods for each SNP are shown in Table 1 -
additional file 1. We genotyped SNP3 by pyrosequencing
analysis on a PSQ™96MA Pyrosequencer according to the
manufacturer's specifications with a biotinylated reverse
primer (5'-CGCCTACTCCTGGTGACTTC-3'), and the
sequencing primer (5'-CGCCCCCATGTGT-3'). The other
10 SNPs were genotyped by direct sequencing, as previ-
ously described [7]. The raw data of direct sequencing
were compiled on PolyPhred [22].Page 2 of 6
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To control genotyping errors, Hardy-Weinberg equilib-
rium (HWE) was checked in the control samples by the
χ2-test (d.f. = 1). We evaluated the statistical differences in
genotype and allele frequencies between cases and con-
trols by the χ2-test (d.f. = 2) and the Fisher's exact proba-
bility test (d.f. = 1), respectively. The magnitude of LD was
evaluated in D' and r2 using the haplotype frequencies
estimated by the EH program, version 1.14 [23]. Statistical
analysis of the haplotype association was carried out as
previously described [24]. The significance level for all sta-
tistical tests was 0.05.
Results
Genotyping and SNP association analysis
We selected 11 SNPs at average interval of 15.9 kb to cover
the entire SLC1A2 region with LD as described in Materi-
als and Methods. Table 2 - additional file 2.  shows the
results of genotype and allele frequencies of SNPs in case
and control samples. No significant deviation from HWE
in control samples was observed (data not shown). SNP2
showed significant differences in genotype (P = 0.013)
and allele (P = 0.008) frequencies between cases and con-
trols. After Bonferroni corrections, these two P values
became non-significance levels (Pcorr = 0.143, Pcorr =
0.088, respectively).
Pairwise linkage disequilibrium and haplotype association 
analyses
We compared the magnitude of LD for all possible pairs
of the 11 SNPs in controls by calculating D' and r2 (Table
3 - additional file 3. , upper diagonal), because LD around
common alleles can be measured with a modest sample
size of 40–50 individuals to a precision equal to 10–20%
of the asymptotic limit [19]. We observed relatively strong
LD (D' > 0.8) in the seven combinations: SNP4-SNP5 (D'
= 0.800), SNP7-SNP8 (D' = 0.877), SNP8-SNP9 (D' =
0.925), SNP4-SNP11 (D' = 0.838), SNP5-SNP11(D' =
0.999), SNP7-SNP11 (D' = 0.816), SNP9-SNP11 (D' =
0.819). Modest LD (D' > 0.4) was observed in the combi-
nations of adjacent SNPs except for SNP5-SNP6 (D' =
0.286) in the control samples. However, modest LD was
detected in cases in the SNP5-SNP6 combination (D' =
0.497).
We constructed pairwise haplotypes for all of the 55 pos-
sible SNP pairs (Table 3 - additional file 3. , lower diago-
nal). We observed significant associations with
schizophrenia in eight combinations: SNP2-SNP3 (P =
0.0021), SNP2-SNP4 (P = 0.0274), SNP2-SNP5 (P =
0.0054), SNP2-SNP6 (P = 0.0178), SNP2-SNP7 (P = 9.4 ×
10-5), SNP2-SNP9 (P = 0.0354), SNP2-SNP10 (P =
0.0089) and SNP2-SNP11 (P = 0.0216). The combination
of SNP2-SNP7 was the only one remained significant after
Bonferroni correction (Pcorr = 0.0052).
Cumulative analysis using the second sample set
In this study, we detected significant associations of one
haplotype in the SLC1A2 region with schizophrenia in the
Kyushu samples. To confirm the positive finding, we
investigated the second Japanese sample set recruited
from the Aichi area. Although significant association of
the disease was observed with neither genotype, allele fre-
quencies of SNP2 (P = 0.195, P = 0.178, respectively), nor
haplotypes of SNP2-SNP7 (P = 0.084) in the second sam-
ple set, the significant haplotype association of SNP2-
Genomic organization of SLC1A2 and locations of the SNPsFigure 1
Genomic organization of SLC1A2 and locations of the SNPs. Exons are shown as vertical bars with exon numbers. 
Eleven SNPs are indicated by circles. Distances between the SNPs are indicated above with kb.
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the two sample sets (P = 5.0 × 10-4) (Table 4 - additional
file 4. ).
Discussion
SLC1A2 is located on the chromosomal region of 11p13-
p12, to which no evidence has been reported for linkage
of schizophrenia, [25,26]. However, there is still a possi-
bility that SLC1A2 is a candidate for schizophrenia sus-
ceptibility genes, because linkage studies could only
detect genes with the large genotype relative risk [27]. We
carried out the genotyping of 100 cases and 100 controls
for 11 SNPs, which were selected to cover the entire
SLC1A2 region with LD. Since minor allele frequencies of
each SNP we tested ranges from 0.220 to 0.485, the
expected detection power of our case-control study is
from 0.89 to 0.94 for the susceptibility gene assuming 2
for genotype relative risk [28].
Modest LD (D' = 0.925 ~ 0.409) was observed in the com-
binations of neighboring SNPs except for SNP5-SNP6 (D'
= 0.286) in the control samples, suggesting that there may
be a recombination hot spot present in the small region
(7.8 kb) between the two SNPs (Table 3 - additional file 3.
). We plotted the magnitude of LD with the physical dis-
tance for each pair of the SNPs, and estimated the average
half-length of LD to be 31.8 kb by assuming a linear
regression (Fig. 2). This is approximately half of the
previously estimated size 60 kb in a United States popula-
tion of north-European descent [21].
Significant associations of schizophrenia with genotype
(P = 0.013) and allele (P = 0.008) frequencies of SNP2
(rs4755404) were detected (Table 2 - additional file 2. ).
However, none of these "single-marker" associations sur-
vived after Bonferroni corrections. An A-G transition in
codon 206, causing a substitution of serine for asparagine,
was identified in the exon 5 of SLC1A2 in a heterozygous
sporadic ALS patient [29]. Since located in a putative gly-
cosylation site, the nonsynonymous SNP is potentially
involved in the pathophysiology of schizophrenia
through affecting the glycosylation status and the trans-
port activity of SLC1A2 [30]. No occurrence of the G allele
of the SNP in 124 Italian schizophrenic and 50 control
subjects has been reported [30]. We found also only A
allele of the SNP in the 100 controls and 100 cases of the
Kyushu samples (data not shown).
In pairwise haplotype association analyses, SNP2 consist-
ently showed significant haplotype associations. The P
value of the combination SNP2-SNP7 was still significant
even after Bonferroni correction (P = 9.4 × 10-5, Pcorr =
0.0052). In our second sample set, the Aichi sample, no
significant association of SNP2 was observed in any of the
analyses of genotypes, alleles and haplotypes. Cumulative
analyses of the two sample sets, however, provide the rep-
lication of the significant haplotype association of SNP2-
SNP7 with schizophrenia (P = 5.0 × 10-4). The frequency
of the G-C haplotype in schizophrenics (26.6%) was nota-
bly higher than in controls (5.6%), suggesting that the G-
C haplotype may be a risk haplotype for schizophrenia.
We observed that the G-C haplotype frequency of schizo-
phrenics (20.0%) was only slightly higher than controls
(14.2%) in the Aichi sample, suggesting a less contribu-
tion of this locus on schizophrenia pathogenesis in the
Aichi sample, although no apparent difference in clinical
subtypes between both sample sets studied in this paper.
The positive association reported here needs to be vali-
dated in larger sample sets, and it would also be worth-
while to search for functional SNPs in the region spanning
SNP2-SNP7.
Conclusion
We concluded that at least one susceptibility locus for
schizophrenia is probably located within or nearby
SLC1A2 in the Japanese population.
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